For research use only. Not for therapeutic Use.
Narmafotinib (AMP-945) is an inhibitor of the enzyme focal adhesion kinase (FAK, KD=0.21 nM). Narmafotinib inhibits autophosphorylation of 397Y-FAK in MDA-MB-231 cells with an IC50=7 nM and exhibits low general cellular toxicity (IC50=2.7 μM, MDA-MB-231 cells)[1][2].
| Catalog Number | I045078 |
| CAS Number | 1393653-34-3 |
| Synonyms | 2-[2-[2-[2-[2-methoxy-4-(1-methylpiperidin-4-yl)anilino]-5-(trifluoromethyl)pyrimidin-4-yl]ethyl]phenyl]acetamide |
| Molecular Formula | C28H32F3N5O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C28H32F3N5O2/c1-36-13-11-19(12-14-36)21-8-10-24(25(15-21)38-2)35-27-33-17-22(28(29,30)31)23(34-27)9-7-18-5-3-4-6-20(18)16-26(32)37/h3-6,8,10,15,17,19H,7,9,11-14,16H2,1-2H3,(H2,32,37)(H,33,34,35) |
| InChIKey | AWJVIOYPZZZYAX-UHFFFAOYSA-N |
| SMILES | CN1CCC(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)CCC4=CC=CC=C4CC(=O)N)C(F)(F)F)OC |
| Reference | [1]. Street I, et al. Abstract LB-308: combination of CTx-0294945 a highly selective inhibitor of focal adhesion kinase with bevacizumab in pre-clinical models of breast cancer[J]. Cancer Research, 2012, 72(8_Supplement): LB-308-LB-308. [2]. Amplia Therapeutics completes single-dose study of AMP945 |
